AstraZeneca PLC (AZN)
NASDAQ: AZN · Real-Time Price · USD
63.20
-0.60 (-0.94%)
At close: Nov 20, 2024, 4:00 PM
63.74
+0.54 (0.85%)
Pre-market: Nov 21, 2024, 5:47 AM EST
AstraZeneca Revenue
AstraZeneca had revenue of $13.57B in the quarter ending September 30, 2024, with 18.04% growth. This brings the company's revenue in the last twelve months to $51.21B, up 13.81% year-over-year. In the year 2023, AstraZeneca had annual revenue of $45.81B with 3.29% growth.
Revenue (ttm)
$51.21B
Revenue Growth
+13.81%
P/S Ratio
n/a
Revenue / Employee
$569,588
Employees
89,900
Market Cap
195.32B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | 24.38B | 2.29B | 10.38% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 87.70B |
| Merck & Co. | 63.17B |
| AbbVie | 55.53B |
| Novartis AG | 49.94B |
| Thermo Fisher | 42.37B |
| Abbott Laboratories | 41.22B |
| Amgen | 32.53B |
| Danaher | 23.74B |
AZN News
- 1 day ago - AstraZeneca awards $3.5M for projects to improve access to healthcare for patients across the US - Business Wire
- 2 days ago - GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study - PRNewsWire
- 3 days ago - Lunit Announces Collaboration with AstraZeneca to Develop AI-Powered Digital Pathology Risk Assessment Tools for NSCLC - PRNewsWire
- 5 days ago - Vaccine Maker Stocks Slump After RFK Jr. Nominated as HHS Head - Investopedia
- 5 days ago - European And US Vaccine Stocks Are Under Pressure - Here's WHy - Benzinga
- 6 days ago - Pharma shares hit as Trump picks RFK Jr to lead health department - The Guardian
- 7 days ago - AstraZeneca: Strong Growth Potential And Market Volatility Offer Opportunity - Seeking Alpha
- 8 days ago - Healthy Returns: AstraZeneca expands U.S. investment plan on confidence in economy - CNBC